Author

S. Oltean

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Assay:DNA methylation· 1 Organism:Drosophila· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. E. Housden· 1 shared A. P. Lynch· 1 shared A. Sharma· 1 shared A. V. Benest· 1 shared A. Zahed· 1 shared A. Zawia· 1 shared B. Braithwaite· 1 shared B. E. Housden· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. E. Housden

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease

S. R. Bhalla, M. Wahid, J. Amartey, A. Zawia, F. Riu, Y. Gao, J. Agrawal, A. P. Lynch, M. J. Machado, T. Hawtrey, R. Kikuchi, K. R. Green, L. Teboul, C. Allen, Z. Blackley, , D. O. Bates

This paper shows that inhibiting SRPK1 in monocytes promotes angiogenesis by altering VEGF splicing from anti-angiogenic VEGF-A165b to pro-angiogenic VEGF-A165a in both human and mouse models of peripheral arterial disease.

bioRxiv · Apr 17, 2024Physiology

Inhibition of autophagy as a novel therapy for the treatment of neurofibromatosis type 1 tumors

M. Stevens, Y. Wang, S. J. Bouley, T. R. Mandigo, A. Sharma, S. Sengupta, A. E. Housden, S. Oltean, N. Perrimon, J. A. Walker, B. E. Housden

This study identifies autophagy inhibitors as potential therapies for NF1 tumors by showing their effectiveness in Drosophila and human models.

bioRxiv · Dec 20, 2021Cancer Biology

The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor

D. Legge, L. Ling, W. Moriarty, D. Lee, M. Szemes, A. Zahed, L. Panousopoulus, W. Y. Chung, Y. Aghabi, J. Barratt, R. Williams, K. Pritchard-Jones, K. Malik, S. Oltean, K. W. Brown

This study identifies ESRP2 as an epigenetically repressed tumour suppressor in Wilms tumour through DNA hypermethylation, showing its ability to inhibit proliferation and suppress tumour growth.

bioRxiv · Nov 2, 2020Cancer Biology